{
"description": "Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen.",
"sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2020",
"_filename": "ConceptMap-mii-cm-onko-atc-transitions-2021.json",
"package_name": "de.medizininformatikinitiative.kerndatensatz.onkologie",
"date": "2024-12-12",
"group": [ {
"source": "http://fhir.de/CodeSystem/bfarm/atc",
"target": "http://fhir.de/CodeSystem/bfarm/atc",
"element": [ {
"code": "L01XE01",
"target": [ {
"code": "L01EA01",
"comment": "Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren",
"display": "Imatinib",
"equivalence": "equivalent"
} ],
"display": "Imatinib"
}, {
"code": "L01XE06",
"target": [ {
"code": "L01EA02",
"display": "Dasatinib",
"equivalence": "equivalent"
} ],
"display": "Dasatinib"
}, {
"code": "L01XE08",
"target": [ {
"code": "L01EA03",
"display": "Nilotinib",
"equivalence": "equivalent"
} ],
"display": "Nilotinib"
}, {
"code": "L01XE14",
"target": [ {
"code": "L01EA04",
"display": "Bosutinib",
"equivalence": "equivalent"
} ],
"display": "Bosutinib"
}, {
"code": "L01XE24",
"target": [ {
"code": "L01EA05",
"display": "Ponatinib",
"equivalence": "equivalent"
} ],
"display": "Ponatinib"
}, {
"code": "L01XE02",
"target": [ {
"code": "L01EB01",
"comment": "Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren",
"display": "Gefitinib",
"equivalence": "equivalent"
} ],
"display": "Gefitinib"
}, {
"code": "L01XE03",
"target": [ {
"code": "L01EB02",
"display": "Erlotinib",
"equivalence": "equivalent"
} ],
"display": "Erlotinib"
}, {
"code": "L01XE13",
"target": [ {
"code": "L01EB03",
"display": "Afatinib",
"equivalence": "equivalent"
} ],
"display": "Afatinib"
}, {
"code": "L01XE35",
"target": [ {
"code": "L01EB04",
"display": "Osimertinib",
"equivalence": "equivalent"
} ],
"display": "Osimertinib"
}, {
"code": "L01XE15",
"target": [ {
"code": "L01EC01",
"comment": "Reklassifizierung zu BRAF-Inhibitoren",
"display": "Vemurafenib",
"equivalence": "equivalent"
} ],
"display": "Vemurafenib"
}, {
"code": "L01XE23",
"target": [ {
"code": "L01EC02",
"display": "Dabrafenib",
"equivalence": "equivalent"
} ],
"display": "Dabrafenib"
}, {
"code": "L01XE46",
"target": [ {
"code": "L01EC03",
"display": "Encorafenib",
"equivalence": "equivalent"
} ],
"display": "Encorafenib"
}, {
"code": "L01XE16",
"target": [ {
"code": "L01ED01",
"comment": "Reklassifizierung zu ALK-Inhibitoren",
"display": "Crizotinib",
"equivalence": "equivalent"
} ],
"display": "Crizotinib"
}, {
"code": "L01XE28",
"target": [ {
"code": "L01ED02",
"display": "Ceritinib",
"equivalence": "equivalent"
} ],
"display": "Ceritinib"
}, {
"code": "L01XE36",
"target": [ {
"code": "L01ED03",
"display": "Alectinib",
"equivalence": "equivalent"
} ],
"display": "Alectinib"
}, {
"code": "L01XE43",
"target": [ {
"code": "L01ED04",
"display": "Brigatinib",
"equivalence": "equivalent"
} ],
"display": "Brigatinib"
}, {
"code": "L01XE44",
"target": [ {
"code": "L01ED05",
"display": "Lorlatinib",
"equivalence": "equivalent"
} ],
"display": "Lorlatinib"
}, {
"code": "L01XE25",
"target": [ {
"code": "L01EE01",
"comment": "Reklassifizierung zu MEK-Inhibitoren",
"display": "Trametinib",
"equivalence": "equivalent"
} ],
"display": "Trametinib"
}, {
"code": "L01XE38",
"target": [ {
"code": "L01EE02",
"display": "Cobimetinib",
"equivalence": "equivalent"
} ],
"display": "Cobimetinib"
}, {
"code": "L01XE41",
"target": [ {
"code": "L01EE03",
"display": "Binimetinib",
"equivalence": "equivalent"
} ],
"display": "Binimetinib"
}, {
"code": "L01XE33",
"target": [ {
"code": "L01EF01",
"comment": "Reklassifizierung zu CDK4/6-Inhibitoren",
"display": "Palbociclib",
"equivalence": "equivalent"
} ],
"display": "Palbociclib"
}, {
"code": "L01XE42",
"target": [ {
"code": "L01EF02",
"display": "Ribociclib",
"equivalence": "equivalent"
} ],
"display": "Ribociclib"
}, {
"code": "L01XE50",
"target": [ {
"code": "L01EF03",
"display": "Abemaciclib",
"equivalence": "equivalent"
} ],
"display": "Abemaciclib"
}, {
"code": "L01XE09",
"target": [ {
"code": "L01EG01",
"comment": "Reklassifizierung zu mTOR-Inhibitoren",
"display": "Temsirolimus",
"equivalence": "equivalent"
} ],
"display": "Temsirolimus"
}, {
"code": "L01XE10",
"target": [ {
"code": "L01EG02",
"display": "Everolimus",
"equivalence": "equivalent"
} ],
"display": "Everolimus"
}, {
"code": "L01XE07",
"target": [ {
"code": "L01EH01",
"comment": "Reklassifizierung zu HER2-Inhibitoren",
"display": "Lapatinib",
"equivalence": "equivalent"
} ],
"display": "Lapatinib"
}, {
"code": "L01XE45",
"target": [ {
"code": "L01EH02",
"display": "Neratinib",
"equivalence": "equivalent"
} ],
"display": "Neratinib"
}, {
"code": "L01XE18",
"target": [ {
"code": "L01EJ01",
"comment": "Reklassifizierung zu JAK-Inhibitoren",
"display": "Ruxolitinib",
"equivalence": "equivalent"
} ],
"display": "Ruxolitinib"
}, {
"code": "L01XE17",
"target": [ {
"code": "L01EK01",
"comment": "Reklassifizierung zu VEGFR-Inhibitoren",
"display": "Axitinib",
"equivalence": "equivalent"
} ],
"display": "Axitinib"
}, {
"code": "L01XE34",
"target": [ {
"code": "L01EK03",
"display": "Tivozanib",
"equivalence": "equivalent"
} ],
"display": "Tivozanib"
}, {
"code": "L01XE27",
"target": [ {
"code": "L01EL01",
"comment": "Reklassifizierung zu BTK-Inhibitoren",
"display": "Ibrutinib",
"equivalence": "equivalent"
} ],
"display": "Ibrutinib"
}, {
"code": "L01XE51",
"target": [ {
"code": "L01EL02",
"display": "Acalabrutinib",
"equivalence": "equivalent"
} ],
"display": "Acalabrutinib"
}, {
"code": "L01XX47",
"target": [ {
"code": "L01EM01",
"comment": "Reklassifizierung zu PI3K-Inhibitoren",
"display": "Idelalisib",
"equivalence": "equivalent"
} ],
"display": "Idelalisib"
}, {
"code": "L01XX61",
"target": [ {
"code": "L01EM02",
"display": "Copanlisib",
"equivalence": "equivalent"
} ],
"display": "Copanlisib"
}, {
"code": "L01XE04",
"target": [ {
"code": "L01EX01",
"comment": "Reklassifizierung zu andere Proteinkinase-Inhibitoren",
"display": "Sunitinib",
"equivalence": "equivalent"
} ],
"display": "Sunitinib"
}, {
"code": "L01XE05",
"target": [ {
"code": "L01EX02",
"display": "Sorafenib",
"equivalence": "equivalent"
} ],
"display": "Sorafenib"
}, {
"code": "L01XE12",
"target": [ {
"code": "L01EX04",
"display": "Vandetanib",
"equivalence": "equivalent"
} ],
"display": "Vandetanib"
}, {
"code": "L01XE21",
"target": [ {
"code": "L01EX05",
"display": "Regorafenib",
"equivalence": "equivalent"
} ],
"display": "Regorafenib"
}, {
"code": "L01XE26",
"target": [ {
"code": "L01EX07",
"display": "Cabozantinib",
"equivalence": "equivalent"
} ],
"display": "Cabozantinib"
}, {
"code": "L01XE29",
"target": [ {
"code": "L01EX08",
"display": "Lenvatinib",
"equivalence": "equivalent"
} ],
"display": "Lenvatinib"
}, {
"code": "L01XE31",
"target": [ {
"code": "L01EX09",
"display": "Nintedanib",
"equivalence": "equivalent"
} ],
"display": "Nintedanib"
}, {
"code": "L01XE39",
"target": [ {
"code": "L01EX10",
"display": "Midostaurin",
"equivalence": "equivalent"
} ],
"display": "Midostaurin"
}, {
"code": "L01XE52",
"target": [ {
"code": "L01EX11",
"display": "Quizartinib",
"equivalence": "equivalent"
} ],
"display": "Quizartinib"
}, {
"code": "L01XE53",
"target": [ {
"code": "L01EX12",
"display": "Larotrectinib",
"equivalence": "equivalent"
} ],
"display": "Larotrectinib"
}, {
"code": "L01XE54",
"target": [ {
"code": "L01EX13",
"display": "Gilteritinib",
"equivalence": "equivalent"
} ],
"display": "Gilteritinib"
}, {
"code": "L01XX14",
"target": [ {
"code": "L01XF01",
"comment": "Reklassifizierung zu Retinoide",
"display": "Tretinoin",
"equivalence": "equivalent"
} ],
"display": "Tretinoin"
}, {
"code": "L01XX22",
"target": [ {
"code": "L01XF02",
"display": "Alitretinoin",
"equivalence": "equivalent"
} ],
"display": "Alitretinoin"
}, {
"code": "L01XX25",
"target": [ {
"code": "L01XF03",
"display": "Bexaroten",
"equivalence": "equivalent"
} ],
"display": "Bexaroten"
}, {
"code": "L01XX32",
"target": [ {
"code": "L01XG01",
"comment": "Reklassifizierung zu Proteasom-Inhibitoren",
"display": "Bortezomib",
"equivalence": "equivalent"
} ],
"display": "Bortezomib"
}, {
"code": "L01XX45",
"target": [ {
"code": "L01XG02",
"display": "Carfilzomib",
"equivalence": "equivalent"
} ],
"display": "Carfilzomib"
}, {
"code": "L01XX50",
"target": [ {
"code": "L01XG03",
"display": "Ixazomib",
"equivalence": "equivalent"
} ],
"display": "Ixazomib"
}, {
"code": "L01XX38",
"target": [ {
"code": "L01XH01",
"comment": "Reklassifizierung zu Histon-Deacetylase-Inhibitoren",
"display": "Vorinostat",
"equivalence": "equivalent"
} ],
"display": "Vorinostat"
}, {
"code": "L01XX39",
"target": [ {
"code": "L01XH02",
"display": "Romidepsin",
"equivalence": "equivalent"
} ],
"display": "Romidepsin"
}, {
"code": "L01XX42",
"target": [ {
"code": "L01XH03",
"display": "Panobinostat",
"equivalence": "equivalent"
} ],
"display": "Panobinostat"
}, {
"code": "L01XX49",
"target": [ {
"code": "L01XH04",
"display": "Belinostat",
"equivalence": "equivalent"
} ],
"display": "Belinostat"
}, {
"code": "L01XX43",
"target": [ {
"code": "L01XJ01",
"comment": "Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren",
"display": "Vismodegib",
"equivalence": "equivalent"
} ],
"display": "Vismodegib"
}, {
"code": "L01XX63",
"target": [ {
"code": "L01XJ03",
"display": "Glasdegib",
"equivalence": "equivalent"
} ],
"display": "Glasdegib"
}, {
"code": "L01XX46",
"target": [ {
"code": "L01XK01",
"comment": "Reklassifizierung zu PARP-Inhibitoren",
"display": "Olaparib",
"equivalence": "equivalent"
} ],
"display": "Olaparib"
}, {
"code": "L01XX54",
"target": [ {
"code": "L01XK02",
"display": "Niraparib",
"equivalence": "equivalent"
} ],
"display": "Niraparib"
}, {
"code": "L01XX60",
"target": [ {
"code": "L01XK04",
"display": "Talazoparib",
"equivalence": "equivalent"
} ],
"display": "Talazoparib"
}, {
"code": "L01XX17",
"target": [ {
"code": "L01CE01",
"comment": "Reklassifizierung zu Topoisomerase-I-Inhibitoren",
"display": "Topotecan",
"equivalence": "equivalent"
} ],
"display": "Topotecan"
}, {
"code": "L01XX19",
"target": [ {
"code": "L01CE02",
"display": "Irinotecan",
"equivalence": "equivalent"
} ],
"display": "Irinotecan"
} ]
} ],
"meta": {
"profile": [ "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap", "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap" ],
"extension": [ {
"url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode": "CC-BY-4.0"
}, {
"url": "http://hl7.org/fhir/StructureDefinition/package-source",
"extension": [ {
"url": "packageId",
"valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
}, {
"url": "version",
"valueString": "2027.0.0-ballot.1"
}, {
"url": "uri",
"valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
} ]
} ]
},
"publisher": "Medizininformatik Initiative",
"jurisdiction": [ {
"coding": [ {
"code": "DE",
"system": "urn:iso:std:iso:3166",
"display": "Germany"
} ]
} ],
"purpose": "Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge.",
"name": "MII_CM_Onko_ATC_Transitions_2021",
"type": null,
"experimental": "false",
"resourceType": "ConceptMap",
"title": "MII CM Onko ATC Code Changes 2020 to 2021",
"package_version": "2027.0.0-ballot.1",
"extension": [ {
"url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode": "shareable"
}, {
"url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode": "publishable"
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept": {
"coding": [ {
"code": "package",
"system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"display": "Package"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate": "2026-09-15"
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept": {
"coding": [ {
"code": "C3262",
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail": {
"telecom": [ {
"value": "thomas.debertshaeuser@charite.de",
"system": "email"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail": {
"name": "Taskforce Core Data Set"
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail": {
"name": "Interoperability Working Group",
"telecom": [ {
"value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group",
"system": "url"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail": {
"name": "National Steering Committee",
"telecom": [ {
"value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee",
"system": "url"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail": {
"name": "Interoperability Working Group",
"telecom": [ {
"value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group",
"system": "url"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail": {
"name": "National Steering Committee",
"telecom": [ {
"value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee",
"system": "url"
} ]
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding": {
"code": "semver",
"system": "http://hl7.org/fhir/version-algorithm",
"display": "SemVer"
}
}, {
"url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod": {
"start": "2027"
}
} ],
"targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
"status": "active",
"id": "c5a9f21f-73d7-408a-b1ab-28850c8b4301",
"kind": null,
"url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021",
"version": "2027.0.0-ballot.1",
"contact": [ {
"name": "Medizininformatik Initiative",
"telecom": [ {
"value": "https://www.medizininformatik-initiative.de/",
"system": "url"
} ]
} ]
}